| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [PubChem] |
| Indication |
For prophylaxis and treatment of bacterial infections. |
| Pharmacology |
Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Biotransformation |
No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. |
| Half Life |
In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged |
| Protein Binding |
Cefotetan is 88% plasma protein bound. |
| Elimination |
No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations. |
| Distribution |
* 10.4 L [elderly patients (greater than 65 years) with normal renal function]
* 10.3 L [healthy volunteers (aged 25 to 28 years)] |
| Clearance |
* 1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)]
* 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)] |
| External Links |
|